ArticleNature communications2025
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Inferring tissue origin from cell-free DNA in metastatic cancer.Cancer metastasis reviews · 2026Review
- Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026Review
- Review
- Applications of circulating tumor cells in esophageal cancer detection and treatment.Discover oncology · 2026Review
- Ridge-assisted micro positioning of cells in a channel.Science advances · 2026Article
- Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Cell therapy manufacturing at full clinical scale: enhancing the quality CAR-T cell therapy starting materials through massively parallel automated microfluidic cell sorting.Lab on a chip · 2026Article
- Band-stop microfluidics for high-purity, label-free enrichment of viable cancer cells from whole blood.Lab on a chip · 2026Article
- Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab.Cancer discovery · 2026Article
- Nature-Inspired Solutions: Biomimetic Materials and Adaptive Devices for Precision Urinary Oncology.Cancers · 2026Review
- Liquid Biopsy in Uterine Leiomyosarcoma: Current Biomarkers, Emerging Technologies, and Future Perspectives.Current oncology reports · 2026Review
- Cascading inertial microfluidics for high-throughput, multi-scale enrichment of tumor cells and intact clusters towards enhanced malignancy diagnosis.Microsystems & nanoengineering · 2026Article
- Review
- Microfluidic automation improves oocyte recovery from follicular fluid of patients undergoing in vitro fertilization.Nature medicine · 2026Article
- From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas.Cellular and molecular neurobiology · 2026Review
- The role of molecular profiling for castration-resistant prostate cancer treatment and therapy development.Frontiers in cell and developmental biology · 2026Review
- Cancer and Aging Biomarkers: Classification, Early Detection Technologies and Emerging Research Trends.Biosensors · 2025Review
- Single-cell RNA-sequencing of circulating tumour cells: A practical guide to workflow and translational applications.Cancer metastasis reviews · 2025Review
- Liquid biopsy of circulating tumor cells: From isolation, enrichment, and genome sequencing to clinical applications.Histology and histopathology · 2025Review
- Ridge-assisted Micro Positioning of Cells and Particles in a Microchannel.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
33 authors.
Avanish Mishra *Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Shih-Bo Huang *Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.ORCID 0000-0002-1048-2344
Taronish DubashKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.
Risa BurrKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.
Jon F EddCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Ben S WittnerKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.ORCID 0000-0001-5657-9849
Quinn E CunneelyCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Victor R PutaturoCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Akansha DeshpandeCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Ezgi AntmenCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Kaustav A GopinathanCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.ORCID 0000-0002-4082-1052
Keisuke OtaniKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.ORCID 0000-0002-8275-0651
Yoshiyuki MiyazawaKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.ORCID 0000-0002-8416-2394
Ji Eun KwakKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.
Sara Y GuayKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.
Justin KellyKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.
John WalshCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Linda T NiemanKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.
Isabella GallerDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.
PuiYee ChanDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.
Michael S LawrenceKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.ORCID 0000-0002-1307-459X
Ryan J SullivanDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.ORCID 0000-0001-5344-6645
Aditya BardiaDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.
Douglas S MicalizziKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.
Lecia V SequistDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.
Richard J LeeDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.
Joseph W FransesDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.
David T TingKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.ORCID 0000-0002-3261-2322
Patricia A R BrunkerDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Shyamala MaheswaranKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA.
David T MiyamotoKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA. dmiyamoto@mgh.harvard.edu.ORCID 0000-0003-3692-8823
Daniel A HaberKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, 02129, USA. DHABER@mgh.harvard.edu.ORCID 0000-0003-1378-6551
Mehmet TonerCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA. mehmet_toner@hms.harvard.edu.ORCID 0000-0002-3647-3665
Funding
Bio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4MMedical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7MHigh-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cellsR01CA255602 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., MAHESWARAN, SHYAMALA · 2021 to 2025
$3.2MMicrofluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancerU01CA268933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Melissa Abel, Mehmet Toner · 2022 to 2026
$3.0MMetastasis and biophysics of clusters of circulating tumor cells in the microcirculationU01CA214297 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., MAHESWARAN, SHYAMALA · 2018 to 2022
$2.9MMicrofluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsyR01CA260304 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., MAHESWARAN, SHYAMALA · 2021 to 2025
$2.2MPrecision Apheresis: stem cell isolation from patients with sickle cell disease for gene therapy using high-throughput microfluidicsK25HL169816 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Avanish Mishra · 2023 to 2026
$550kMicrofluidic Apheresis to Isolate Circulating Tumor ClustersR21CA260989 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2022 to 2023
$428kNCI NIH HHS R01 CA255602NCI NIH HHS R01 CA260304NCI NIH HHS R21 CA260989NCI NIH HHS U01 CA214297NCI NIH HHS U01 CA268933NHLBI NIH HHS K25 HL169816NIBIB NIH HHS P41 EB002503NIGMS NIH HHS T32 GM144273U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA255602U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R21CA260989U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U01CA214297U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) K25HL169816U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB) P41EB002503
Abstract
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we developed a high-throughput microfluidic device, depleting hematopoietic cells through high-flow channels and force-amplifying magnetic lenses. Here, we apply this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volume of 5.83 liters from seven patients with metastatic cancer. High CTC yields (mean 10,057 CTCs per patient; range 100 to 58,125) reveal considerable intra-patient heterogeneity. CTC size varies within patients, with 67% overlapping in diameter with WBCs. Paired single-cell DNA and RNA sequencing identifies subclonal patterns of aneuploidy and distinct signaling pathways within CTCs. In prostate cancers, a subpopulation of small aneuploid cells lacking epithelial markers is enriched for neuroendocrine signatures. Pooling of CNV-confirmed CTCs enables whole exome sequencing with high mutant allele fractions. High-throughput CTC enrichment thus enables cell-based liquid biopsy for comprehensive monitoring of cancer.
Indexed as
LeukapheresisNeoplastic Cells, CirculatingAneuploidyBiomarkers, TumorExome SequencingFemaleHigh-Throughput Nucleotide SequencingHumansLiquid BiopsyMaleMicrofluidic Analytical TechniquesMicrofluidicsNeoplasmsProstatic NeoplasmsSingle-Cell AnalysisBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.